Michael J. Mitten
AbbVie (United States)(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Peptidase Inhibition and Analysis, Protein Degradation and Inhibitors, Cell death mechanisms and regulation, HER2/EGFR in Cancer Research
Most-Cited Works
- → An inhibitor of Bcl-2 family proteins induces regression of solid tumours(2005)3,369 cited
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor(2008)1,942 cited
- → Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy(2015)535 cited
- → Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity(2014)328 cited
- → Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models(2016)308 cited
- → Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL(2007)294 cited
- → Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo(2005)244 cited
- → Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models(2008)209 cited
- Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208(2013)